| Similar Articles |
|---|
 |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.   |
Pharmaceutical Executive
April 1, 2014
William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
Pharmaceutical Executive
November 1, 2014
William Looney |
Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market. |
Pharmaceutical Executive
March 1, 2014
William Looney |
The Call to Community: A Conversation with Dr. David Nash Population health is the foundation for much of what is truly new in US health reform. For big Pharma, it represents yet another escalation in expectations. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease. |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
December 1, 2011
William Looney |
The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda. |
Pharmaceutical Executive
January 1, 2013
William Looney |
The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace. |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
Pharmaceutical Executive
July 10, 2014
William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. |
Pharmaceutical Executive
February 1, 2012
Sarah Krug |
Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. |
CIO
September 26, 2013
Stephanie Overby |
Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines. |
Pharmaceutical Executive
July 10, 2014
Ben Comer |
WebMD: The Patient Value Equation For WebMD CEO David Schlanger, connecting patients with physicians through a robust digital platform delivers the winning formula necessary to achieve quality of care, cost savings, and better health outcomes. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
Managed Care
August 2004
Alan Lotvin |
Specialty Pharmacy Presents Unique Set of Challenges Only a small percent of a typical health plan's population takes medicine for conditions outside the generalist's scope. But it's a big portion of the drug bill. |
The Motley Fool
June 12, 2006
Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
Pharmaceutical Executive
August 1, 2011 |
Employers: Fighting Non-Adherence A Q and A with Andrew Webber, President and CEO of the National Business Coalition on Health |
Managed Care
December 2005
Martin Sipkoff |
Reports Confirm High Value of Step-Therapy Programs Tiered benefit design and mail order pharmacy are useful, but don't overlook this other significant vehicle for savings: step therapy programs. |
Pharmaceutical Executive
July 1, 2005 |
Marketing to Professionals: Shaping the Future of Medicine Pharma will focus on approving safer, more effective drugs that have real-life applications. |
CFO
March 1, 2012
David McCann |
Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies. |
The Motley Fool
March 4, 2005
Tom Taulli |
In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors. |
The Motley Fool
August 5, 2004
Tim Beyers |
Will Lawsuit Hurt Express Scripts? Although investors seem to be over the initial jitters arising from Express Scripts' problems, the stock is still down more than 12% since New York Attorney General Eliot Spitzer filed a lawsuit accusing the pharmacy benefits manager of fraud. |
The Motley Fool
July 25, 2011
Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
American Family Physician
March 15, 2002
Khalid Almoosa |
Is Thrombolytic Therapy Effective for Pulmonary Embolism? No evidence from clinical trials proves that thrombolytic therapy reduces the recurrence rate of pulmonary embolism or affects mortality in hemodynamically stable patients... |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk. |
The Motley Fool
December 19, 2006
Matthew Crews |
Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over. |
The Motley Fool
April 13, 2009
Brian Orelli |
Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion. |
The Motley Fool
July 30, 2009
Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool
October 29, 2009
Brian Orelli |
Expressing Itself Nicely A nice quarter for Express Scripts. |
Nursing
April 2009
Pruitt & Lawson |
What You Need to Know About Venous Thromboembolism Do you know how to recognize and respond to this potentially life-threatening emergency? |
The Motley Fool
February 23, 2006
Stephen D. Simpson |
Express Scripts Overdue for a Pause This pharmacy benefits manager is posting very good growth and has room for improvement, but what about the stock price? |
The Motley Fool
August 24, 2010
David Meier |
Can Express Scripts Produce Big Returns? Express Scripts generates incredible returns on equity. Let's see how they do it. |
